Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased risk for fracture. In the FREEDOM study, denosumab reduced fracture risk and increased bone mineral density (BMD). We report the spine and hip dual-energy X-ray absorptiometry (DXA) BMD responses from the overall study of 7808 women and from a substudy of 441 participants in which more extensive spine and hip assessments as well as additional skeletal sites were evaluated. Significant BMD improvements were observed as early as 1mo at the lumbar spine, total hip, and trochanter (all p<0.005 vs placebo and baseline). BMD increased progressively at the lumbar spine, total hip, femoral neck, trochanter, 1/3 radius, and total body from baseline to months 12, 24, and 36 (all p<0.005 vs placebo and baseline). BMD gains above the least significant change of more than 3\% at 36 months were observed in 90\% of denosumab-treated subjects at the lumbar spine and 74\% at the total hip, and gains more than 6\% occurred in 77\% and 38\%, respectively. In conclusion, denosumab treatment resulted in significant, early, and continued BMD increases at both trabecular and cortical sites throughout the skeleton over 36mo with important gains observed in most subjects.

Denosumab Significantly Increases DXA BMD at Both Trabecular and Cortical Sites: Results From the FREEDOM Study / M.A. Bolognese; C.S. Teglbjærg; J.R. Zanchetta; K. Lippuner; M.R. McClung; M.L. Brandi; A. Høiseth; P. Lakatos; A.H. Moffett ;R. S. Lorenc; A. Wang; C. Libanati. - In: JOURNAL OF CLINICAL DENSITOMETRY. - ISSN 1094-6950. - ELETTRONICO. - 16:(2012), pp. 147-153. [10.1016/j.jocd.2012.02.006]

Denosumab Significantly Increases DXA BMD at Both Trabecular and Cortical Sites: Results From the FREEDOM Study.

BRANDI, MARIA LUISA;
2012

Abstract

Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased risk for fracture. In the FREEDOM study, denosumab reduced fracture risk and increased bone mineral density (BMD). We report the spine and hip dual-energy X-ray absorptiometry (DXA) BMD responses from the overall study of 7808 women and from a substudy of 441 participants in which more extensive spine and hip assessments as well as additional skeletal sites were evaluated. Significant BMD improvements were observed as early as 1mo at the lumbar spine, total hip, and trochanter (all p<0.005 vs placebo and baseline). BMD increased progressively at the lumbar spine, total hip, femoral neck, trochanter, 1/3 radius, and total body from baseline to months 12, 24, and 36 (all p<0.005 vs placebo and baseline). BMD gains above the least significant change of more than 3\% at 36 months were observed in 90\% of denosumab-treated subjects at the lumbar spine and 74\% at the total hip, and gains more than 6\% occurred in 77\% and 38\%, respectively. In conclusion, denosumab treatment resulted in significant, early, and continued BMD increases at both trabecular and cortical sites throughout the skeleton over 36mo with important gains observed in most subjects.
2012
16
147
153
M.A. Bolognese; C.S. Teglbjærg; J.R. Zanchetta; K. Lippuner; M.R. McClung; M.L. Brandi; A. Høiseth; P. Lakatos; A.H. Moffett ;R. S. Lorenc; A. Wang; C. Libanati
File in questo prodotto:
File Dimensione Formato  
Denosumab significantly increases DXA BMD.pdf

Accesso chiuso

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Tutti i diritti riservati
Dimensione 507.18 kB
Formato Adobe PDF
507.18 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/771136
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 38
social impact